Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,353 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Positron emission tomography Clear all

Conditions: Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions: Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography; Procedure · Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2036
U.S. locations: 106
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more

Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab, Venetoclax, Zanubrutinib; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 150
States / cities: Tucson, Arizona • Irvine, California • Coral Gables, Florida + 113 more

Conditions: Malignant Melanoma, Metastatic
Interventions: Pembrolizumab, FLT PET; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
Interventions: Computed Tomography, Iodine I 124, Iodine I-131, Laboratory Biomarker Analysis, Pharmacodynamic Study, Positron Emission Tomography, Trametinib; Procedure · Other · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Uterine Cervical Neoplasms
Interventions: [F18]Fluorothymidine; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Alzheimer Disease, Sleep Apnea
Interventions: PET Scan and nocturnal polysomnography; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years to 75 Years
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: carbon-11 acetate PET scan; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Male only
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer s Disease, Mild Cognitive Impairment, Healthy
Interventions: 18F-PF974, 18F-florbetaben; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 50 Years to 100 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection
Interventions: 18F-fluciclovine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
Interventions: [18F]APN-1607; Drug
Lead sponsor: APRINOIA Therapeutics, LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: New Haven, Connecticut • Mount Arlington, New Jersey • New York, New York

Conditions: Healthy Volunteers
Interventions: ITI-1284 10 mg, ITI-1284 20 mg; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anorexia Nervosa
Interventions: Positron emission tomography (PET) imaging; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Oxytocin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Anesthesia, Healthy
Interventions: Dexmedetomidine, Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Postoperative Cognitive Dysfunction
Interventions: Florbetapir F 18 (18F-AV-45), no intervention; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 65 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiovascular Risk Factor, Circadian Dysregulation, Obesity
Interventions: Positron Emission Tomography (PET) scanning of cardiac function at 3 time points across the 24 hour circadian cycle; Combination Product
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy Volunteers
Interventions: [11C]UCB-J, Brivaracetam, Levetiracetam; Radiation · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: [18F] MNI-946, [18F]Florbetapir; Drug
Lead sponsor: Invicro; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy; Drug · Diagnostic Test · Procedure
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 169
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 129 more

Conditions: Lung Cancer
Interventions: carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy; Drug · Genetic · Procedure + 1 more
Lead sponsor: American College of Radiology Imaging Network; Network
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 46
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more

Conditions: Aging
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 110 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

MRI and PET to Assess Pembrolizumab Response

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

FLT PET Imaging for Cervical Cancer

Sleep Aging and Risk for Alzheimer's 2.0

Positron Emission Tomography in Prostate Cancer

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants

New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

Kappa Opioid Receptor Imaging in Anorexia

Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia

Neurochemical Mechanisms of the Awake vs. Anesthetized Brain

Effects of Brain Beta-Amyloid on Postoperative Cognition

Body Weight, Sleep, and Heart Health

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)